RLAY Relay Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: RLAY

Price (delayed)

$14.51

Market cap

$2.78B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.56

Enterprise value

$2.61B

?
Relative Growth: Rel. Growth: 51
Relative Strength: Rel. Strength: 97
Relative Valuation: Rel. Valuation: 1
Relative Profitability: Rel. Profitability: 37

Relay Therapeutics, Inc. operates as a biotechnology company. The Company develops durgs for the treatment of cancer. Relay Therapeutics serves customers in the United States.

Highlights
The debt has contracted by 33% YoY and by 2.7% from the previous quarter
The EPS has increased by 29% year-on-year and by 3.1% since the previous quarter
Relay Therapeutics's revenue has increased by 39% YoY but it has decreased by 30% from the previous quarter
RLAY's gross profit is up by 39% year-on-year but it is down by 30% since the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://relaytx.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of RLAY

RLAY stock price

How has the Relay Therapeutics stock price performed over time
Intraday
-5.16%
1 week
4.39%
1 month
10.85%
1 year
349.23%
YTD
71.51%
QTD
45.83%

Financial performance

How have Relay Therapeutics's revenue and profit performed over time
Revenue
$10.68M
Gross profit
$10.68M
Operating income
-$296.46M
Net income
-$272.71M
Gross margin
100%
Net margin
-2,554.1%
Relay Therapeutics's operating margin has increased by 44% YoY but it has decreased by 41% from the previous quarter
The net margin has contracted by 42% from the previous quarter but it has grown by 41% YoY
Relay Therapeutics's revenue has increased by 39% YoY but it has decreased by 30% from the previous quarter
RLAY's gross profit is up by 39% year-on-year but it is down by 30% since the previous quarter

Price vs fundamentals

How does RLAY's price correlate with its fundamentals

Growth

What is Relay Therapeutics's growth rate over time

Valuation

What is Relay Therapeutics stock price valuation
P/E
N/A
P/B
4.04
P/S
244.41
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
244.03
The EPS has increased by 29% year-on-year and by 3.1% since the previous quarter
The P/B is 124% higher than the last 4 quarters average of 1.9 and 85% higher than the 5-year quarterly average of 2.3
The equity is up by 13% since the previous quarter but it has declined by 11% year-on-year
The stock's price to sales (P/S) is 134% more than its last 4 quarters average of 110.2 but 49% less than its 5-year quarterly average of 501.3
Relay Therapeutics's revenue has increased by 39% YoY but it has decreased by 30% from the previous quarter

Efficiency

How efficient is Relay Therapeutics business performance
The return on sales has declined by 42% since the previous quarter but it has increased by 41% year-on-year
The return on invested capital has declined by 8% since the previous quarter and by 5% year-on-year
The ROA is down by 2.3% QoQ

Dividends

What is RLAY's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for RLAY.

Financial health

How did Relay Therapeutics financials performed over time
Relay Therapeutics's total liabilities has decreased by 27% YoY but it has increased by 6% from the previous quarter
RLAY's total assets is up by 13% QoQ but it is down by 12% YoY
The debt is 95% less than the equity
The debt has contracted by 33% YoY and by 2.7% from the previous quarter
Relay Therapeutics's debt to equity has decreased by 29% YoY and by 17% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.